Clinical Trial Update: Dapagliflozin for Cardio-renal Protection After ICU Discharge [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating dapagliflozin for cardio-renal protection after ICU discharge in patients with heart failure and chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Heart Failure

Drugs mentioned

• Forxiga (dapagliflozin)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Heart Failure and Chronic Kidney Disease Post-ICU | Phase 3 | Status: RECRUITING